<DOC>
	<DOC>NCT00755989</DOC>
	<brief_summary>Morphine gel applied topically to wounds will reduce wound pain and decrease patients use of oral and intravenous pain medications, therefore reducing side effects.</brief_summary>
	<brief_title>Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds</brief_title>
	<detailed_description>Patients will be randomized to receive either placebo (versa base gel) or morphine gel to wound. Patients receiving morphine gel will have a decrease in pain score and use less oral/intravenous pain medications.</detailed_description>
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<criteria>Signed and dated consent form &amp; HIPAA &gt; 18 yo Single stage 23 wound No allergy to morphine Alert and oriented (thinking ability clear and intact, physician approval) English language proficiency Allergy to morphine, codeine, or versa base, pts taking medications for acute condition, other than for the wound pain Patients with neuropathies Patients with respiratory conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>